Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences (DiSFeB), University of Milan, Milan, Italy.
IRCCS MultiMedica, Sesto San Giovanni, Milan, Italy.
Curr Atheroscler Rep. 2024 Nov 25;27(1):10. doi: 10.1007/s11883-024-01248-w.
To consolidate key information on the efficacy and safety of ezetimibe, with a focus on the latest evidence.
While ezetimibe has long been used alongside statins to help achieve lipid goals when statins are insufficient or in statin-intolerant patients, recent studies confirm and extend its benefits. Ezetimibe, when added to statins, is now recognized as an effective option for high-risk cardiovascular patients. Additionally, for those intolerant to statins, it can be combined with bempedoic acid, offering significant LDL cholesterol reduction. Ezetimibe's favourable tolerability, with fewer side effects than statins, along with the availability of fixed-dose combinations, enhances both treatment efficacy and patient adherence. Overall, this review underscores ezetimibe's evolving role in lipid management, providing valuable guidance for optimizing cardiovascular risk reduction strategies.
总结依折麦布在疗效和安全性方面的关键信息,重点关注最新证据。
依折麦布长期以来一直与他汀类药物联合使用,以帮助在他汀类药物不足或他汀类药物不耐受患者中实现血脂目标,最近的研究证实并扩展了其益处。依折麦布联合他汀类药物,现在被认为是心血管高危患者的有效选择。此外,对于那些不能耐受他汀类药物的患者,它可以与贝匹地酸联合使用,显著降低 LDL 胆固醇。依折麦布的耐受性良好,副作用比他汀类药物少,并且有固定剂量组合,提高了治疗效果和患者的依从性。总的来说,本综述强调了依折麦布在血脂管理中的不断发展的作用,为优化心血管风险降低策略提供了有价值的指导。